Amplo Biotechnology, Inc.

Amplo Biotechnology, Inc. is a US-based company focused on developing innovative gene therapies for neuromuscular diseases, aiming to address significant unmet medical needs through advanced treatment solutions. Founded in 2019 and headquartered in Pompano Beach, US, Amplo Biotechnology, Inc. specializes in gene therapy solutions targeting neuromuscular junction disorders.

The company has successfully completed four funding deals, with its latest being a Seed round on May 29, 2023, raising USD 2. 24 mn. The company is led by CEO Patricio Sepulveda, whose background includes founding other ventures in the biotech sector. Amplo Biotechnology specializes in developing gene therapies that target diseases of the neuromuscular junction (NMJ), focusing on two primary product candidates: AMP-101 and AMP-201.

AMP-101 is an AAV-Dok7 gene therapy for treating Congenital Myasthenic Syndromes (CMS) and other neuromuscular disorders, while AMP-201 is an AAV-Collagen-Q gene therapy designed to treat ColQ CMS. Both therapies are undergoing preclinical studies and are expected to progress to clinical trials within the next 10-12 months, with an aim to serve patients globally, particularly in North America and Europe. Amplo Biotechnology’s revenue model is based on collaborations and partnerships with research institutions, healthcare organizations, and potentially biopharmaceutical companies as it advances its product candidates. The company anticipates generating revenue through therapeutic sales of AMP-101 and AMP-201 upon successful clinical development and regulatory approval, utilizing agreements where healthcare providers procure therapies either directly or via specialty distributors with pre-negotiated pricing.

Amplo Biotechnology plans to utilize its recent grant funding received on May 29, 2023, from The National Institute of Arthritis and Musculoskeletal and Skin Diseases to advance its product AMP-201. The company aims to enter the clinical trial phase for AMP-201 within the next 10-12 months, while continuing to focus on global markets, particularly North America and Europe, where neuromuscular diseases significantly affect patient quality of life.